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Abstract 27 
The growth inhibitory properties of a 5-nitrothiazole series was evaluated against 28 
Trypanosoma brucei. A subset of related compounds displayed the greatest potency towards 29 
the parasite while exhibiting little cytotoxic effect on mammalian cells, with this anti-30 
parasitic activity being dependent on expression of a type I nitroreductase by the 31 
trypanosome. We conclude that the 5-nitrothiazole class of nitroheterocycle may represent 32 
new leads in the treatment of human African trypanosomiasis. 33 
34 
Spread via the blood feeding habits of tsetse flies, parasites belonging to the Trypanosoma 35 
brucei complex are responsible for human African trypanosomiasis (HAT) (1). Drugs 36 
represent the only option to combat this infection but their use is often problematic (2). One 37 
treatment that targets the cerebral stage of this disease is a nifurtimox-eflornithine 38 
combination therapy (3, 4). In this medication eflornithine acts as an inhibitor of ornithine 39 
decarboxylase, blocking polyamine biosynthesis (5, 6) while nifurtimox is converted to a 40 
toxic metabolite following activation by a type I nitroreductase (NTR) (7, 8). As type I NTRs 41 
are expressed by some unicellular eukaryotes but not by metazoan organisms, the 42 
bioreductive activity of this enzyme has been exploited to develop a series of novel anti-43 
parasitic agents that often exhibit little or no toxicity towards cultured mammalian cells (9 & 44 
10).  45 
 46 
The 5-nitrothiazoles represent a class heterocyclic compounds of which niridazole and 47 
nitazoxanide display potent antimicrobial and antihelmintic activities (11, 12). The mode(s) 48 
of action of these agents is unclear with both structures shown to inhibit of key enzymes 49 
involved in energy metabolism (13, 14) and able to function as prodrugs, undergoing 50 
reduction to form adduct forming metabolites (15-17). To date only niridazole and its 51 
derivatives have been screened for trypanocidal activity against T. brucei with this in 52 
combination with suramin able to cure mice of trypanosomiasis (18). However, concerns over 53 
its carcinogenic properties resulted in trials using niridazole being suspended (19). Here, we 54 
assessed a 2-amide 5-nitrothiazole series for growth inhibitory activity against bloodstream 55 
form (BSF) T. brucei (Table 1). Out of the fifteen compounds tested, seven had no effect on 56 
trypanosomal growth at a concentration of 30 µM. For the remaining chemicals, detailed 57 
inhibition assays were conducted generating dose response curves from which IC50s were 58 
determined (Table 1). For NT2, NT4, NT6, NT7 and NT11 an appreciable trypanocidal 59 
activity (IC50’s >10.0 µM) equivalent to the potency exhibited by nifurtimox was noted with 60 
the other agents being less effective (IC50s ~17 µM). Screening against two mammalian lines 61 
(Table 1) revealed that NT2, NT10, NT12 and NT15 displayed toxicity towards THP-1 or 62 
SK-N-SH cells with NT10 and NT12 having growth inhibitory effects against both lines. For 63 
the remaining agents no growth inhibitory effect at concentrations up to 100 µM was 64 
observed.  65 
 66 
Before mediating its trypanocidal effects nifurtimox must undergo activation in a reaction 67 
catalysed by a type I NTR (7). Using purified HIS-tagged TbNTR (Fig. 1A) we evaluated 68 
whether the 2-amide 5-nitrothiazoles series could serve as substrates for this enzyme (Fig. 69 
1B). Five compounds were shown to be “good” NTR substrates, generating a specific activity 70 
~3-fold greater than that noted for nifurtimox (Fig. 1B). Of these structures, NT2, NT4, NT6 71 
and NT7 are related in that they contained a saturated unbranched hydrocarbon chain. 72 
However, the number of carbon atoms in this sequence and the associated increase in 73 
lipophilicity did not affecting the specific activity displayed by TbNTR towards a given 74 
substrate. Of the remaining compounds, three yielded activities similar to that observed for 75 
nifurtimox while the others were not metabolised by TbNTR at an appreciable rate under the 76 
conditions used here (Fig. 1B). 77 
 78 
To investigate whether NTR plays a role in prodrug activation within the parasite itself the 79 
susceptibility of BSF T. brucei engineered to over express this enzyme was evaluated (Table 80 
1; Fig. 2) (8). Cells having elevated levels of TbNTR were up to 10-fold more sensitive to 81 
NT2, NT4, NT6 or NT7 than controls. This effect was NTR specific as recombinant and wild 82 
type parasite lines displayed similar sensitivities to the non-nitroaromatic compound G418 83 
(IC50 ~0.6 µM). When these studies were extended to test other trypanocidal nitrothiazoles, a 84 
lower (~2) fold or no difference in IC50 was observed (Table 1; Fig. 2). This implies that for 85 
these less effective trypanocidal compounds, NTR plays little or no role in the metabolism of 86 
these structures within the parasite itself. 87 
 88 
By comparing the specific activity values and growth inhibitory effects of each compound, a 89 
number of structure activity relationships (SARs) were identified. In contrast to their non-90 
substituent counterparts’ addition of a methyl or tert-butyl group at the 4-position on the 91 
thiazole ring generated compounds that were not TbNTR substrates and did not exhibit 92 
trypanocidal activities: compare NT2 with NT3 and NT4 with NT5. This lack of activity 93 
could be due to steric hindrance with the 4-alkyl side chain blocking the trypanosomal 94 
enzyme from gain access to the adjacent 5-nitro grouping or could reflect an inductive effect 95 
with the alkyl substituent on the thiazole backbone rendering nitroreduction energetically 96 
unfavourable. Extending the SAR studies to investigate grouping attached to the thiazole ring 97 
via a 2-amide linker revealed that compounds containing an unbranched, saturated 98 
hydrocarbon chain (NT2, NT4, NT6, NT7) were efficiently metabolised by TbNTR with this 99 
translating to a trypanocidal effect equivalent to that of the reference nitrofuran. 100 
Encouragingly, these structures displayed also little/no in vitro toxicity to mammalian cells 101 
suggesting that they warrant in vivo analysis. Modification of this saturated linear 102 
hydrocarbon chain (incorporation of an unsaturated bond (NT8) or an ether linkage (NT13), 103 
inclusion of halogen substituents (NT10-12) or its replacement with a hydrogen atom (NT1) 104 
or a benzyl-containing grouping (NT9, NT15)) generated structures that displayed lower 105 
TbNTR activity and/or had reduced potency towards BSF trypanosomes. Presumably, such 106 
alterations to the saturated alkyl chain alter the affinity these variants have for the parasite 107 
oxidoreductase. As the broad spectrum ant-infective agent nitazoxanide is structurally related 108 
to NT9 and NT15 (all contain a phenyl group attached to the amide linker) we predict that 109 
this particular antimicrobial agent is unlikely to function as an effective TbNTR substrate 110 
and/or display activity against BSF T. brucei. Intriguingly, despite being screened against a 111 
wide range of microbial infectious agents including Trypanosoma cruzi and Leishmania the 112 
potency of this particular nitrothiazole against T. brucei has not been reported. 113 
 114 
There has been renewed interest in the use of nitroheterocyclic prodrugs for the treatment of 115 
trypanosomatid infections with nifurtimox in combination with eflornithine now being used 116 
to treat the form of HAT prevalent in West and Central Africa while the nitroimidazole 117 
fexinidazole is under clinical evaluation against HAT, Chagas disease and visceral 118 
leishmaniasis. In both cases these nitroheterocycles are converted to toxic metabolites by a 119 
type I NTR activity (7, 20). Here, we have identified several trypanocidal nitrothiazoles, 120 
including some that are activated by the type I NTR, as being potent against BSF T. brucei as 121 
nifurtimox. Promisingly the most effective structures exhibited little or no toxicity to cultured 122 
mammalian cells with trypanosomal expression of the type I NTR underlying their 123 
selectivity. As such, these compounds warrant further attention in terms of developing novel 124 
therapies targeting HAT and could potentially represent one component of a new 125 
combinatorial treatment against this disease. 126 
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Table 1. Structure and growth inhibitory properties of nitrothiazole compounds. All compounds tested satisfy the Lipinski’s Rule of 5 (see 200 
PubChem database (http://pubchem.ncbi.nlm.nih.gov/)). Susceptibility of parasites and mammalian cells to nitrothiazole compounds was 201 
assessed as previously described (7). Average IC50 values ± standard deviations were calculated from dose response curves performed in 202 
triplicate. TbNTRox represents the T. brucei cell line overexpressing the type I nitroreductase. The figures in parenthesis correspond to the fold 203 
difference in IC50 values of the TbNTRox, SK-N-SH and THP-1 cell lines when compared against wild type. 204 
 205 
      
compound Structure  IC50 (μM) 
 T. brucei Mammalian line 
 R1 R2  wild type TbNTRox SK-N-SH THP-1 
NT1 H H  >30.00    
NT2 CH3 H  4.67 ± 0.34 0.58 ± 0.11 (8) >100.00 (>21) 86.97 ± 0.99 (19) 
NT3 CH3 CH3  >30.00    
NT4 CH2CH3 H  3.67 ± 0.50 0.51 ± 0.09 (7) >100.00 (>27) >100.00 (>27) 
NT5 CH2CH3 C(CH3)3  >30.00    
NT6 CH2CH2CH3 H  6.47 ± 0.06 0.64 ± 0.13 (10) >100.00 (>15) >100.00 (>15) 
NT7 CH2CH2CH2CH3 H  4.32 ± 0.90 0.57 ± 0.02 (8) >100.00 (>23) >100.00 (>23) 
NT8 CH2CHCH2 H  >30.00    
NT9 benzyl H  >30.00    
NT10 CH2Cl H  16.12 ± 0.97 13.53 ± 0.50 (1) 18.33 ± 0.68 (1) 7.68 ± 0.56 (<1) 
NT11 C(F)3 H  8.87 ± 0.70 11.24 ± 0.58 (1) >100.00 (>11) >100.00 (>11) 
NT12 CH(Br)CH3 H  17.41 ± 1.08 8.37 ± 1.84 (2) 19.83 ± 0.44 (1) 21.53 ± 0.19 (1) 
NT13 CH2OCH3 H  >30.00    
NT14 C(CH3)2CH3 CH3  >30.00    
NT15 3,5 dichlorobenzyl H  16.26 ± 1.24 8.17 ± 0.61 (2) >100.00 (>6) 6.75 ± 1.08 (<1) 
NFX    4.12 ± 0.13 0.31 ± 0.06 (13) >100.00 (>24) 64.80 ± 1.50 (16) 
 206 
Figure 1. Activity of TbNTR toward different nitrothiazoles. (A) Samples obtained during purification of recombinant TbNTR were 
analysed on by SDS-PAGE (10 %) stained with Coomassie blue. E. coli crude extract (lane 1) was loaded onto a Ni-NTA column and the flow 
through (lane 2) collected. The column was washed with 50 mM imidazole (lane 3) and 100 mM imidazole (lane 4) containing buffers. 
Recombinant protein was eluted in a buffer containing 500 mM imidazole; 0.5 % Triton X-100 (lane 5). Markers (M) are in kiloDaltons. The 
~30 kDa band corresponding to recombinant TbNTR is indicated. (B) Activity of purified recombinant TbNTR was assessed by using 
nitrothiazoles (NT1-15) as substrate (100 M) at a fixed concentration of NADH (100 M). Enzyme activity, expressed in nmoles of NADH 
oxidised per minute per mg TbNTR, was then calculated using an ε value of 6,220 M-1 cm-1. Nfx (nifurtimox) was used as control and enzyme 
activity determined as previously described (7). The enzyme activity values are the means of data from 3 assays ± standard deviations. 
Figure 2. Susceptibility of bloodstream form T. brucei over expressing TbNTR to nitrothiazoles. Dose-response curves of T. brucei (solid 
line) and parasites expressing an ectopic copy of Tbntr (dashed line) towards representative nitrothiazoles. The growth inhibitory effect 
expressed as IC50 values was determined (see Table 2). All data points are mean values ± standard deviations from experiments performed in 
quadruplicate. Nifurtimox was used as drug control. 
